Is this a new treatment fir ED that coykd help after RARP

  • 2 replies
  • 142 subscribers
  • 114 views

My husband had nerve sparing RARP 7 months ago. It may still be early days but he takes 5mg of tadalafil every day and the 'event dose' just causes a headache so far!

Does anyone know if a device called Vertica that I've just read about has helped in cases where it's presumably nerve damage that is the problem? 

  • He's not able to use injections because he's on blood thinners  and not keen on that idea anyway. This sounds like a much gentler aid!
  • Hello Cathy ( 

    As a peer to peer Community we are unable to give medical advice so unless we have a Community member who has used this device we are unable to comment.

    As with anything medical you need to speak with your team or in this case an ED specialist. 

    (I am aware of the product and it retails between £ 1250 and £ 1500!! Open mouth).

    Best wishes - Brian.

    Community Champion badge

    Macmillan Support Line - 0808 808 00 00, 7 days a week between 8am-8pm

    Strength, Courage, Faith, Hope, Defiance, VICTORY.

    I am a Macmillan volunteer.

  • No experience of this device, but a couple of thoughts...

    The Vertica clinical trial excluded patients with any pelvic cancer in the previous 3 years, and only had 28 patients with ED, which is a very small number for a trial. It was not a randomised control trial.

    In the case of ED caused by prostatectomy, the "fault" is not in the penis, so a device which treats the penis is unlikely to be able to fix it.

    There are loads of causes of ED, and they don't seem to have evaluated which causes the patients had (except none would have been due to prostatectomy in previous 3 years). They don't seem to know how the device might be improving erectile function, but they suggest heating.

    This does not suggest any likely benefit for patients with damaged erection nerves.

    Radiofrequency energy in the treatment of erectile dysfunction – a novel cohort pilot study on safety, applicability, and short-term efficacy